What happened

Dean Takahashi of GamesBeat reported via Techmeme that Astromech, which uses genomic data to build predictive AI models of biological change, raised $20 million at a $3.8 billion valuation, bringing its total funding to $60 million.

Related Techmeme coverage in the same signal window also noted Pathway raising a $30 million seed at a $500 million valuation for its Post-Transformer BDH architecture, and San Francisco-based Vals raising a $40 million Series A led by a16z at a $400 million valuation for real-world AI evaluations and benchmarks.

Evidence

• Astromech raised $20M at a $3.8B valuation with $60M total funding for genomic predictive AI models.

  Techmeme · attributed

  Astromech, which uses genomic data to build predictive AI models of biological change, raised $20M at a $3.8B valuation, bringing its total funding to $60M

• GamesBeat attributed the Astromech financing report on Techmeme.

  Techmeme · attributed

  Dean Takahashi / GamesBeat : Astromech, which uses genomic data to build predictive AI models of biological change, raised $20M at a $3.8B valuation, bringing its total funding to $60M

• Pathway raised a $30M seed at a $500M valuation for Post-Transformer BDH architecture models.

  Techmeme · attributed

  Pathway, which is developing AI models based on what it calls its "Post-Transformer" BDH architecture, raised a $30M seed at a $500M valuation

• Vals raised a $40M Series A led by a16z at a $400M valuation for real-world AI evaluations.

  Techmeme · attributed

  SF-based Vals, which develops evaluations and benchmarks to test AI models on real-world tasks, raised a $40M Series A led by a16z at a $400M valuation

• Vals reported eightfold revenue growth since 2025 in related Techmeme coverage.

  Techmeme · attributed

  Vals, a San Francisco-based company specializing in real-world AI model evaluations, secured a $40M Series A led by a16z at a $400M valuation. The company reports eightfold revenue growth since 2025

Why it matters

Capital is clustering around narrow vertical models, non-Transformer architectures, and paid evaluation layers, which reshapes where builders should invest research and validation effort.

Limits and uncertainties

The cited Techmeme items do not disclose Astromech revenue, named customers, or round participants.

Pathway and Vals coverage in the packet is limited to funding amounts, valuations, and brief product descriptions without independent performance benchmarks.

Practical implications

Teams building life-sciences AI should plan for genomic-data pipelines and domain-specific validation rather than relying on general LLM benchmarks alone.

Operators deploying models should treat third-party real-world evaluation vendors as part of release infrastructure, not optional QA.

What to watch

Whether Astromech publishes concrete predictive-model results, partnerships, or customer deployments beyond the disclosed funding figures.

Follow-on rounds or product releases from Pathway and Vals that tie valuations to measurable architecture or evaluation performance.